Thank you, Paul. The continued momentum in both our U.S. and international businesses during Q3 saw over 14 million average ...
Novo Nordisk remains a dominant business with a strong pipeline, and current multiples are low enough to justify a buy. Read my latest analysis of NVO stock.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback